Form 8-K - Current report:
SEC Accession No. 0001193125-24-286212
Filing Date
2024-12-30
Accepted
2024-12-30 07:50:30
Documents
13
Period of Report
2024-12-30
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d920512d8k.htm   iXBRL 8-K 26700
  Complete submission text file 0001193125-24-286212.txt   145541

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA amlx-20241230.xsd EX-101.SCH 2848
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE amlx-20241230_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amlx-20241230_pre.xml EX-101.PRE 10811
15 EXTRACTED XBRL INSTANCE DOCUMENT d920512d8k_htm.xml XML 3505
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 241586962
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)